MATTHEW RHADANS: Open Payments
NPI 1073874905 · HIGGINSVILLE, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$831 in 47 payments from 17 companies in 2025. Trend: 2023 $875 · 2024 $800 · 2025 $831
Food & beverage: $831
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 11 | $162 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $105 |
| Teva Pharmaceuticals USA, Inc. | 5 | $92 |
| Lilly USA, LLC | 5 | $83 |
| AstraZeneca Pharmaceuticals LP | 5 | $82 |
| ABBVIE INC. | 3 | $62 |
| E.R. Squibb & Sons, L.L.C. | 3 | $46 |
| Dexcom, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Tonix Medicines, Inc. | 1 | $23 |
Products named: Wegovy, CAPLYTA, AIRSUPRA, AUSTEDO XR, MOUNJARO, VRAYLAR, COBENFY, JARDIANCE.
Industry payments across MO — which companies pay providers there.
